New trial aims to match diabetes drugs to patients for better heart and kidney protection

NCT ID NCT07594145

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This phase 2 trial will test two drugs, finerenone and sotagliflozin, in 57 people with type 1 diabetes who are at risk for heart and kidney problems. The goal is to see if matching the right drug to each person's specific diabetes subtype can improve early signs of heart and kidney health. The study will measure changes in urine protein and a heart stress marker over 26 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
finerenone and sotagliflozin
What this could lead to
If successful, this trial could show that matching specific diabetes subtypes to targeted drugs helps protect the heart and kidneys in people with type 1 diabetes.
What could go wrong
This is a small, early-phase trial (57 people) testing short-term effects. The drugs may not work as hoped, and side effects are possible. Results may not apply to everyone with type 1 diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIO-RENAL VASCULAR FUNCTION AND FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.